Treatment options for deep vein thrombosis

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 7, 2010, Pages 1069-1075

  Squizzato, Alessandro ^a   Dentali, Francesco ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Deep vein thrombosis; Factor Xa inhibitors; Thrombin inhibitors

Indexed keywords

AMIODARONE; ANTIVITAMIN K; APIXABAN; ARGATROBAN; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; DESULFATOHIRUDIN; DIGOXIN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; HIRULOG; IDRAPARINUX; MCC 977; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; OTAMIXABAN; PANTOPRAZOLE; PLACEBO; RECOMBINANT HIRUDIN; RITONAVIR; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; YM 150;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; EPISTAXIS; HEART INFARCTION; HEMATOMA; HEMATURIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; MOLECULE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; RECOMMENDED DRUG DOSE; REVIEW; STROKE; TREATMENT CONTRAINDICATION; TREATMENT WITHDRAWAL; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; FACTOR XA; HUMANS; SECONDARY PREVENTION; THROMBIN; VENOUS THROMBOSIS;

EID: 77951282418     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003690013     Document Type: Review

References (41)

1. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1:1309-1312
2. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edition. Chest 2008;133(6 Suppl):454S-545S (Pubitemid 351892971)
3. Imberti D, Dall'Asta C, Pierfranceschi MG. Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med 2009;4:471-478
4. Squizzato A, Dentali F, Steidl L, Ageno W. New direct thrombin inhibitors. Intern Emerg Med 2009;4:479-484
5. Agnelli G, Becattini C. New oral anticoagulants: just a new therapeutic option or a real breakthrough? Intern Emerg Med 2009;4:455-458
6. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-1040 (Pubitemid 41262337)
7. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edition. Chest 2008;133:234-256 (Pubitemid 351892961)
8. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development. Clin Pharmacokinet 2009;48:1-22
9. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003;109(Suppl 1):S9-S15 (Pubitemid 36724832)
10. Mungall D. BIBR-1048 Boehringer Ingelheim. Curr Opin Invest Drugs 2002;3:905-907 (Pubitemid 36266808)
11. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303 (Pubitemid 47283865)
12. Wienen W, Stassen JM, Priepke H, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost 2007;98:333-338 (Pubitemid 47250236)
13. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009;30:2897-2907
14. European Medicines Agency (EMEA). European public assessment report: Pradaxa [online]. Available from: http://www.emea.europa.eu
15. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185 (Pubitemid 47617868)
16. Eriksson BI, Dahl OE, Rosencher N, et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007;370:949-956 (Pubitemid 47393577)
17. Ginsberg JS, Davidson BL, Comp PC, et al. The oral thrombin inhibitor dabigatran etexilate vs the north american enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;2:1-9
18. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
19. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151 .
20. Available from: http://clinicaltrials.gov/ [Last accessed on 12 January 2010]
21. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous .thromboembolism. N Engl J Med 2009;361:2342-2352
22. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-1426 (Pubitemid 47576022)
23. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-689 (Pubitemid 40216038)
24. Bauer KA. New anticoagulants: anti IIa vs anti Xa----is one better? J Thromb Thrombolysis 2006;21:67-72
25. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-1247 (Pubitemid 46809411)
26. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl) 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl) -4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-5556
27. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2007;6:820-829 (Pubitemid 351524543)
28. Strassburger J, Wilmen A, Pohlmann J, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59--7939----an oral, direct factor Xa inhibitor. J Thromb Haemost 2005;3:514-521 (Pubitemid 41632877)
29. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59--7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-558
30. European Medicines Agency (EMEA). European public assessment report: Xarelto [online]. Available from: http://www.emea.europa.eu
31. Gruber A, Marzec UM, Buetehorn U, et al. Recombinant factor VIIa reverses the effects of a high dose of rivaroxaban in baboons. Pathophysiol Haemost Thromb 2007;36(Suppl 1):abstract A39
32. Perzborn E, Tinel H. FEIBA reverses the effects of a high dose of rivaroxaban in rats. Pathophysiol Haemost Thromb 2007;36(Suppl 1):, abstract A40
33. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
34. Lassen MR, Gallus AS, Pineo GF, Raskob GE. The ADVANCE--2 study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement. J Thromb Haemost 2009;7(2):abstract LB-MO-005
35. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775 (Pubitemid 351930851)
36. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-39
37. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786 (Pubitemid 351930852)
38. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-1680
39. Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009;91:636-644
40. Buller HR, Einstein investigators. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension Study. Blood 2009;114:LBA2 .
41. Van Thiel D, Kalodiki E, Wahi R, et al. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 2009;15:389-394